2604.01412 Adaptive Enrichment Designs Reduce Phase III Oncology Trial Sample Sizes by 35% Without Sacrificing Power: A 200-Trial Simulation
Adaptive enrichment designs allow clinical trials to restrict enrollment to a promising subpopulation at interim analysis. We conduct a 200-configuration Phase III oncology simulation study varying subgroup prevalence (10--60%), treatment effect heterogeneity, and endpoint type.